排序方式: 共有13条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Objective To study the relationship between the change in serum levels of vascular endothelial growth factor(VEGF) and endostatin (ES) after trascatheter arterial chemoembolization (TACE) and the prognosis of patients with liver carcinoma. Methods Serum VEGF and endostatin levels were measured by enzyme-linked immunoassay in 120 patients with hepatocellular carcinoma before and a week after TACE.Results Among patients with large (diameter ≥5 cm) tumors , the serum levels of ES and VEGF before and after TACE are 43.35 ( ±9.80),48.35 ( ± 10.89), 310.23 (±64.31) ,and 369.10 ( ±60. 11) ng/ml respectively. Among patients with portal vein tumor thrombus, the corresponding figures are 54.28 (±8.78 ),50.28 (±7.51), 331.26 (±63.38) and 400.29 (±60.98) ng/ml. The levels of VEGF and ES were significantly related to the presence of portal vein tumor thrombus, the clinicopathological grade and size of the tumor(P <0.05 ). Patients with a higher grade tumor were more likely to have elevated levels of VEGF and ES.So are patients with more advanced stage tumors. In addition, higher levels of VEGF and ES in serum are associated with worse survival. Conclusion Elevated serum VEGF and endostatin levels in patients with hepatocellular carcinoma are closely correlated with the grade and size of the tumor, and the presence of portal vein tumor thrombus. Serum VEGF and ES level may be used for predicting the biological behavior, invasion, metastasis and prognosis of hepatocellular carcinoma. 相似文献
6.
目的 探讨肝细胞癌患者肝动脉化疗栓塞术(TACE)前后血管内皮生长因子(VEGF)和内皮抑素(ES)变化规律与预后的关系.方法 酶联免疫吸附试验(ELISA)法检测患者TACE术前及术后1周血清VEGF和ES水平.结果 肿瘤直径≥5 cm的患者,ES在治疗前后分别为(43.35±9.80)ng/ml、(48.35±10.89)ng/ml;VEGF分别为(310.23±64.31)ng/ml、(369.10±60.11)ng/ml.肿瘤伴有门静脉癌栓的患者ES在治疗前后分别为(54.28±8.78)ng/ml、(50.28±7.51)ng/ml;VEGF分别为(331.26±63.38)ng/ml、(400.29±60.98)ng/ml.VEGF和ES水平与肿瘤大小、门静脉癌栓以及临床分期密切相关(P<0.05).肝细胞癌患者临床分期越晚,TACE前、后VEGF和ES水平均越高.晚期肝癌患者VEGF/ES比值明显高于早期患者.VEGF/ES比值越低生存时间越长.结论 VEGF、ES、VEGF/ES比值可作为预测肝细胞癌治疗效果的指标. 相似文献
7.
目的:观察白细胞介素-24(IL24)基因对肝癌细胞系Bel-7402生长的抑制作用,为肝癌的基因治疗提供理论基础.方法:将真核分泌表达载体pIRES-IL-24转染肝癌细胞系Bel-7402.RT-PCR检测IL-24基因的表达,蛋白质印迹法及ELlSA检测IL-24蛋白的表达,MTT法检测IL-24对肝癌细胞的生长抑制和杀伤作用,流式细胞仪检测细胞的凋亡和细胞周期.结果:pIRES-IL-24能够在Bel-7402中高效表达.细胞培养上清液中IL-24蛋白表达浓度为124.1 ng/mL.IL-24能明显抑制Bel-7402肝癌细胞的生长,转染后第4天抑制率为46.3%,与对照组比较,P<0.05.IL-24促进肝癌细胞的凋亡,凋亡率41.0%,与对照组比较,P<0.05.细胞周期分析显示,IL-24阻滞肝癌细胞在G2/M期.结论:重组表达载体pIRES-IL-24介导IL-24基因在人肝癌细胞中高效表达,可杀伤肝癌细胞Bel-7402,促进细胞增殖阻滞及诱导肿瘤细胞凋亡. 相似文献
8.
9.
1病例报告例1:患者男,38岁。因间断咳嗽咳痰1个月于2004年12月15日收住山东省肿瘤医院。既往无心脏病、脑血管病史。查体:浅表淋巴结未触及肿大,右肺上野呼吸音略低,余无特殊。胸部CT示右肺上叶尖后段不规则结节状影,约4cm×3cm×3cm大小,其内见点状钙化影,边缘模糊,呈分叶状并见粗毛刺及胸膜凹陷征。心电图示:T波低平。血流变示全血黏度值增高,血浆黏度值增高。术前诊断:1)右肺上叶癌;2)右肺上叶炎性假瘤。于2004年12月20日在全麻下行剖右胸右肺上叶占位探查术。术中见胸腔少量胸腔积液,右肺上叶包块约4cm×3cm×3cm大小,质硬,包块周围炎… 相似文献
10.
病历摘要患者男 ,77岁。因腹痛、恶心 6d ,心慌、憋气 1d入院。6d前活动时出现腹痛 ,以剑突下明显 ,持续隐痛 ,阵发加重 ,伴恶心、腹胀感 ,无呕吐、黑便及脓便 ,大便 2次均正常 ,于家中按“胃炎”治疗 ,效果不佳。近 1d来出现胸闷、心慌 ,憋气明显 ,遂来我院就诊。既往体健 ,否认有类似病史及石棉接触史。体检 :T 37℃ ,P 95次 /min ,R 2 4次 /min ,BP 110 / 6 5mmHg(1mmHg =0 133kPa)。神志清晰 ,精神紧张 ,呼吸急促 ,面色苍白 ,言语流利 ,半卧位。浅表淋巴结不大 ,颈静脉充盈 ,气管左移。右侧胸廓饱满 ,呼吸动度减弱 ,语颤减弱 ,叩诊… 相似文献